EVOLUTION AT MERCK - INVENTING FOR LIFE
STRATEGIC BUSINESS DEVELOPMENT
FUELING INNOVATION
Bolt-on acquisitions
Developing portfolio through value-creating
acquisitions
Investments in innovative mechanisms and
technologies
Strategic collaborations and licensing
Meaningful partnerships across all stages of
development
Working with a broad range of partners from
academia to biotech to pharma
Peloton
Therapeutics
IMMUNE DESIGN
Antelliq
Viralytics
Developers of Oncolytic Immunotherapies
Afferent
Tilos
THERAPEUTICS
Vallée
Rigontec GmbH
HARRISVACCINES
AstraZeneca
K
moderna
KalVista
PHARMACEUTICALS
messenger therapeutics
Eisai
SUTRO
NGMBIO
BIOPHARMA
BAYER
BAYER
TEIJIN
¹Peloton expected to close in 3Q 2019
Completed ~60 transactions in 2018 spanning acquisitions,
licensing, technology deals and clinical collaborations
MERCK
INVENTING FOR LIFE
Rob Davis
14View entire presentation